Tatva Chintan reports 37% EBITDA growth in Q1

Tatva Chintan Pharma Chem reported operating revenue of INR1,169 million for Q1 FY26, up 11% year-on-year, with EBITDA jumping 37% to INR173 million. EBITDA margin improved to 14.8% while profit after tax rose to INR66 million from INR52 million.

Structure Directing Agents demand is recovering, with Euro 7 supplies expected from October 2025. Electrolyte Salts revenue increased 32% quarter-on-quarter with new hybrid vehicle orders. The company projects 20-25% revenue growth for the next financial year.